Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients.
As Veloxis is focussing its efforts and resources on the regulatory approval and commercialisation of Envarsus®, the company is discontinuing future efforts to identify partners for its existing pipeline cardiovascular assets.
BUSINESS DEVELOPMENT CONTACT:
John Weinberg, EVP, CCO
Telephone: +1 732-321-3208
Mar 4, 2015
Notice to Convene Annual General Meeting